AB284130

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164]

20ul selling size
RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(27 Publications)

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (ab284130) is a rabbit monoclonal antibody detecting N6-methyladenosine (m6A) in Dot Blot.

- Biophysical QC for unrivalled batch-batch consistency
- Over 20 publications

View Alternative Names

N6-methyladenosine, m6A

3 Images

FRET

Supplier Data

FRET - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

HTRF was performed on 25 nm of each biotinylated oligos and using ab284130 at a concentration range of 0.001-4.000 ug/ml. Species-specific Terbium cryptate- labelled anti-rabbit IgG antibody and D2-labeled Streptavidin were used.

Supplier Data

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot blot analysis of N6-methyladenosine (m6A) using ab284130 at 1/5000 (0.0001μg/mL) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20,000 dilution.

Lane 1 : HeLa total RNA

Lane 2 : HeLa mRNA

Exposure time : 20 seconds

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Supplier Data

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot blot analysis of N6-methyladenosine (m6A) using ab284130 at 1/5000 (0.0001μg/mL) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20,000 dilution.

Lane 1 : m6, 6A-oligo

Lane 2 : A-oligo

Lane 3 : Am-oligo

Lane 4 : m6A-oligo

Lane 5 : m6Am-oligo

Exposure time : 6 seconds

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Carrier free

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23561-164

Isotype

IgG

Carrier free

Applications

Dot, FRET

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "FRET" : {"fullname" : "FRET", "shortname":"FRET"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Modified Amino Acid": { "Dot-species-checked": "notRecommended", "Dot-species-dilution-info": "", "Dot-species-notes": "", "FRET-species-checked": "testedAndGuaranteed", "FRET-species-dilution-info": "0.001-4 µg/mL", "FRET-species-notes": "<p></p>" }, "Modified Nucleic Acid": { "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/5000", "Dot-species-notes": "<p></p>", "FRET-species-checked": "notRecommended", "FRET-species-dilution-info": "", "FRET-species-notes": "" } } }

style

left-column

Product details

What is this antibody validated in?
Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (ab284130) is a rabbit recombinant monoclonal antibody and is validated for use in Dot Blot. Trusted by the scientific community
Anti-N6-methyladenosine (m6A) [EPR23561-164] (ab284130) was first used in a scientific publication in 2021 and has been cited over 20 times in peer-reviewed journals.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.

Other related products
We have a range of other formats of antibody clone [EPR23561-164] also available for your convenience: ab284130, Carrier free - ab284136

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

N6-methyladenosine (m6A) is a chemical modification present in RNA molecules specifically marking the adenosine base with a methyl group at the nitrogen-6 position. This modification weighing approximately 14 Da occurs in diverse eukaryotic species and influences RNA metabolism. m6A methylation can be detected using techniques like m6A dots blot or m6A ELISA. The modification is abundant in tissues like the brain and testis reflecting its critical role in varying cell types. Also m6A is known as a dynamic and reversible mark with its levels continuously adjusted by enzymes called writers (methyltransferases) erasers (demethylases) and readers (RNA-binding proteins).

Biological function summary

M6A methylation affects mRNA processing stability translation and decay. It integrates into large multi-protein complexes where it influences gene expression outcomes by affecting the RNA's interaction with the cellular machinery. This methylation modification acts as a regulatory signal that influences essential processes such as cell differentiation and circadian rhythms. Elucidating the biological functions of m6A involves studying how it affects RNA fate and its downstream gene regulatory networks.

Pathways

M6A modification is central to the mRNA metabolic pathway and the PI3K-Akt signaling pathway. It interacts with various proteins such as METTL3 an m6A methyltransferase which is vital for mediating m6A modification. It also interacts with YTH domain-containing proteins that recognize m6A marks influencing transcript dynamics and gene expression. The interplay of m6A with proteins in these pathways underlines its role in fine-tuning cellular processes and responses.

M6A modification has a significant impact on cancer and neurological disorders. In cancers alterations in m6A methylation patterns can promote oncogenic transformation and metastasis. m6A-related proteins such as FTO an m6A demethylase have shown connections to these pathways affecting cancer progression. In neurological disorders m6A impacts aspects of neural development and function and abnormalities in its regulation may contribute to diseases like Alzheimer's. Understanding the roles of m6A in diverse diseases can pave the way for novel therapeutic approaches.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

See full target information N6-methyladenosine (m6A)

style

left-column

Publications (27)

Recent publications for all applications. Explore the full list and refine your search

Odontology : PubMed38969870

2024

METTL3 promotes immature dental pulp stem cells-induced angiogenesis by regulating ETS1 mRNA stability in an mA-HuR-dependent manner.

Applications

Dot

Species

Human

Jian Qin,Li Zou,Fachao Lu,Fang Liu,Qian Min,Lilei Zhu

Experimental gerontology 194:112496 PubMed38897394

2024

METTL14-mediated methylation of SLC25A3 mitigates mitochondrial damage in osteoblasts, leading to the improvement of osteoporosis.

Applications

Dot

Species

Human

Ping Wang,Weifeng Zhou,Fuhua Chen,Xiaoping Zhang,Qiu Zhang,Yiqing Chen,Nan Zhang

Journal of hazardous materials 472:134440 PubMed38723480

2024

SUMOylation modification of FTO facilitates oxidative damage response of arsenic by IGF2BP3 in an m6A-dependent manner.

Applications

Dot

Species

Human

Hongyang Zhang,Qian Chen,Huifang Han,Changxin Guo,Xuejun Jiang,Yinyin Xia,Yunxiao Zhang,Lixiao Zhou,Jun Zhang,Xin Tian,Lejiao Mao,Jingfu Qiu,Zhen Zou,Chengzhi Chen

International journal of molecular sciences 25: PubMed38674123

2024

Retinoic Acid Upregulates METTL14 Expression and the mA Modification Level to Inhibit the Proliferation of Embryonic Palate Mesenchymal Cells in Cleft Palate Mice.

Applications

Dot

Species

Mouse

Yue Zhu,Yadong Zhang,Yaoqi Jiang,Hongshi Cai,Jianfeng Liang,Hongyu Li,Cheng Wang,Jinsong Hou

Renal failure 46:2322037 PubMed38445367

2024

FTO attenuates TNF-α-induced damage of proximal tubular epithelial cells in acute pancreatitis-induced acute kidney injury via targeting AQP3 in an N6-methyladenosine-dependent manner.

Applications

Unspecified application

Species

Human

Xinghui Li,Qi Liang,Lu Liu,Shujun Chen,Yong Li,Yu Pu

Aging cell 23:e14123 PubMed38380598

2024

METTL14 affects UVB-induced human dermal fibroblasts photoaging via miR-100-3p biogenesis in an mA-dependent manner.

Applications

Dot

Species

Human

Lihao Chen,Yu Hu,Min Zhang,Lihao Liu,Jing Ma,Zhuohong Xu,Jiaan Zhang,Heng Gu,Kun Chen

World journal of oncology 15:100-113 PubMed38274714

2024

Inhibiting the mA Reader IGF2BP3 Suppresses Ovarian Cancer Cell Growth via Regulating PLAGL2 mRNA Stabilization.

Applications

Species

Human

Tian Tian Dai,Yi Ze Li,Hui Ting Hu,Yong Mei Zhao,Hong Yan Peng,Wen Dong Bai,Jing Wen Wang

Cell death & disease 15:62 PubMed38233403

2024

METTL3 facilitates renal cell carcinoma progression by PLOD2 mA-methylation under prolonged hypoxia.

Applications

Dot

Species

Human

Yimeng Chen,Yichen He,Zhengsheng Li,Nan Zhang,Cuixing Zhou,Xiaozhou He,Dong Xue

Redox biology 69:103026 PubMed38184996

2024

Betaine alleviates cognitive impairment induced by homocysteine through attenuating NLRP3-mediated microglial pyroptosis in an mA-YTHDF2-dependent manner.

Applications

Dot

Species

Human

Zhi-Jun Yang,Si-Yu Huang,Kai-Yi Zhong,Wen-Ge Huang,Zi-Hui Huang,Tong-Tong He,Meng-Tao Yang,Maierhaba Wusiman,Dan-Dan Zhou,Si Chen,Bi-Xia Huang,Xiao-Lin Luo,Hua-Bin Li,Hui-Lian Zhu

Environmental health perspectives 131:127023 PubMed38157273

2024

Immunotoxicity Evaluation of Trihalophenolic Disinfection By-Products in Mouse and Human Mononuclear Macrophage Systems: The Role of RNA Epitranscriptomic Modification in Mammalian Immunity.

Applications

Dot, Dot

Species

Human, Mouse

Min Qin,Linyuan Huang,Meishuang Li,Tianye Shao,Jun Zhang,Xiaoqin Jiang,Chenlu Shao,Chengsi Zhao,Yang Pan,Qing Zhou,Yong Wang,Xiao-Min Liu,Jingfan Qiu

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164]

FRET - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (27)

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Product promise